The use of immunotherapy treatment in malignant pheochromocytomas/paragangliomas: a case report
Robin Raquel Rodriguez, Saleha Rizwan, Khaled Alhamad et al. · Journal of Medical Case Reports · 2021
BACKGROUND: Pheochromocytomas are a subset of paragangliomas, which are a rare group of neural crest cell-derived tumors. Malignant cases of both pheochromocytomas and paragangliomas are even rarer, and currently there is no standard of care. This case report details the use of off-label immunotherapy and its efficacy in the management of the aforementioned tumor. CASE PRESENTATION: Herein is presented a case of a 60-year-old Caucasian female with a rare malignant pheochromocytoma. The tumor was determined to be unresectable because of involvement of surrounding organs. Radiation therapy was also not a viable option because of concerns over appreciable toxicity in relation to mass size. As there is no standard of care for malignant cases, the patient was started on chemotherapeutic agents but was soon shown to be intolerant to this treatment. As she was ineligible for several clinical trials, the patient was started on the off-label immunotherapeutic agents nivolumab and ipilimumab. Immunotherapy use resulted in decreased tumor size, improved quality of life, and reconsideration for radiation therapy. CONCLUSIONS: The use of immunotherapy in pheochromocytoma in this patient clearly demonstrated substantial benefit, as she was able to be reconsidered for radiation therapy. Not only has the patient been tolerant of this treatment, but she has exhibited progression-free survival of over 20 months. As there is no current standard treatment for malignant pheochromocytomas, the success of its use in this patient lends support to the ongoing clinical trials regarding the use of immunotherapy in rare tumors, including pheochromocytomas.
Cited by 11 works. doi:10.1186/s13256-021-02733-5 Open-access PDF
Authors
References
- A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
- A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors
- Treatment of Malignant Pheochromocytoma
- Phase 2 study of pembrolizumab in patients with advanced rare cancers
- Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
- Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors
- Malignant and Metastatic Pheochromocytoma: Case Report and Review of the Literature
- Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas
- Correction: Phase 2 study of pembrolizumab in patients with advanced rare cancers
- Long-term treatment with octreotide in a patient with malignant pheochromocytoma: impact on survival and time to tumor progression